Xtl Biopharmaceuticals (XTLB) Fundamental Analysis: Revenue, Earnings & Valuation

1.35 / 10

Underperform

Fundamental rating is Underperform with a 1.4/10 quality score. Strengths include accounts receivable turnover and interest coverage, while fixed‑asset turnover and income‑tax ratio drag performance. Inventory turnover is decent, but overall financial health appears negative, suggesting prudent or no exposure.

Analysis Checks(5/7)

Total operating revenue (YoY growth rate %)

Value292.39

Score2/3

Weight-12.69%

1M Return0.58%

Inventory turnover ratio

Value37.80

Score3/3

Weight13.56%

1M Return-0.67%

Accounts receivable turnover ratio

Value5.47

Score2/3

Weight13.43%

1M Return-0.65%

Income tax / Total profit (%)

Value3.83

Score0/3

Weight30.51%

1M Return-1.54%

Fixed assets turnover ratio

Value2.92

Score1/3

Weight25.16%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value27.72

Score2/3

Weight15.15%

1M Return-0.73%

Cost of sales ratio (%)

Value536.56

Score2/3

Weight14.87%

1M Return-0.74%

Is XTLB undervalued or overvalued?

XTLB scores 1.35/10 on fundamentals and holds a Premium valuation at present. Backed by its -204.16% ROE, -651.65% net margin, -0.98 P/E ratio, -131.47 P/B ratio, and -166.67% earnings growth, these metrics solidify its Underperform investment rating.